Boston Scientific

The MedTech industry comprises companies which develop, manufacture and distribute the technologies, devices, equipment, diagnostic tests and health information systems that are transforming health care through earlier disease detection, less invasive procedures, more effective treatments and quicker recovery times.

In an ageing society in which more and more money is spent on health, the MedTech sector offers excellent investment opportunities. Life-changing technologies allow millions of people to live longer, healthier and more productive lives.

The whole industry is growing well and Boston Scientific is a major player in it, through its market leadership in minimally invasive medical technologies and its range of products which span key therapeutic areas characterised by organic growth and market expansion.

Some sensible acquisitions and partnerships further enhance the company’s competitive positioning and support revenue diversification and a focus on operating efficiencies and cost management support improvements in profit margins and cash flow. 

Boston Scientific faces scrutiny around product safety and the systems in place to ensure it. While animal testing is often required by regulators to demonstrate product efficacy and safety, it raises ethical concerns.

Other risks such as delays in reporting adverse effects, lack of trial diversity, and post-approval recalls can undermine public trust and regulatory confidence. These issues carry potential legal, reputational, and financial consequences.

Social risks exist around equitable access to healthcare where high treatment costs can limit access to some medical devices in low-income and developing regions. Additionally, we continue to monitor supply chain practices, including working conditions and fair wages in manufacturing facilities.